Adaptive Biotechnologies

ADPTNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$4.446 B

$27.86 -2.62%

Close of 21 Sept 2026

Revenue

$277.0M

#2164 by revenue

Earnings

-$59.5M

Loss-making

Shares outstanding

159,595,842

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#22CRISPR TherapeuticsCRSP$5.64B
#23Iovance BiotherapeuticsIOVA$4.62B
#24Adaptive BiotechnologiesADPT$4.45B
#25Relay TherapeuticsRLAY$3.99B
#26Tarsus PharmaceuticalsTARS$3.62B

What if Adaptive Biotechnologies were worth as much as…

Open the what-if tool →

Gold $30.3T

$189,692.00

Per share 6,809× higher

Bitcoin $1.72T

$10,775.99

Per share 387× higher

Nvidia $5.48T

$34,335.84

Per share 1,232× higher

Or at a round number

$10.0B $20.0B $50.0B $100.0B

Where these numbers come from

Share counts and financials for Adaptive Biotechnologies are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.